Published in Cardiol Ther on March 14, 2015
Niacin Plus Statin to Prevent Vascular Events | NCT00120289
Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE (HPS2-THRIVE) | NCT00461630
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study (DESCARTES) | NCT01516879
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities (TESLA) | NCT01588496
Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications. World J Hepatol (2016) 0.77
The panorama of familial hypercholesterolemia in Latin America: a systematic review. J Lipid Res (2016) 0.75
Sitosterolemia Presenting as Pseudohomozygous Familial Hypercholesterolemia. Clin Med Res (2016) 0.75
Correlates of Achieving Statin Therapy Goals in Children and Adolescents with Dyslipidemia. J Pediatr (2016) 0.75
Mutation detection in Chinese patients with familial hypercholesterolemia. Springerplus (2016) 0.75
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet (2005) 32.41
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med (2006) 23.83
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 11.67
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med (2014) 9.25
Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation (1998) 4.39
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014) 4.14
The LDL receptor. Arterioscler Thromb Vasc Biol (2009) 3.78
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev (2006) 3.26
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet (2014) 2.98
Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet (1984) 2.91
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet (2014) 2.91
Lifestyle modification for obesity: new developments in diet, physical activity, and behavior therapy. Circulation (2012) 2.82
A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med (1995) 2.65
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (2008) 2.62
THE INHERITANCE OF ESSENTIAL FAMILIAL HYPERCHOLESTEROLEMIA. Am J Med (1964) 2.36
PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J Am Coll Cardiol (2010) 2.30
Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science (1992) 2.24
Familial hypercholesterolaemia: summary of NICE guidance. BMJ (2008) 2.18
Use of niacin in the United States and Canada. JAMA Intern Med (2013) 2.02
Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol (2013) 2.01
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol (2013) 1.96
Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler Thromb Vasc Biol (2013) 1.95
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 1.92
Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J Am Coll Cardiol (2014) 1.88
Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol (1993) 1.87
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol (2006) 1.85
Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis (2004) 1.78
Familial hypercholesterolemia in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab (2012) 1.70
Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol (2004) 1.61
High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res (2010) 1.56
Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation (2014) 1.53
Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation (2011) 1.51
Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol (2014) 1.45
Improved survival of patients with homozygous familial hypercholesterolaemia treated with plasma exchange. Br Med J (Clin Res Ed) (1985) 1.37
Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun (2014) 1.28
Guidelines for the management of familial hypercholesterolemia. J Atheroscler Thromb (2012) 1.16
Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol (2008) 1.14
Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J (2013) 1.13
Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet (1981) 1.13
Temporary amelioration of hyperlipidemia in low density lipoprotein receptor-deficient rabbits transplanted with genetically modified hepatocytes. Proc Natl Acad Sci U S A (1990) 1.09
A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler Thromb Vasc Biol (2006) 1.03
Living-donor liver transplantation for homozygous familial hypercholesterolemia from a donor with heterozygous hypercholesterolemia. Transpl Int (2003) 0.97
Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis (1997) 0.97
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis (2007) 0.97
Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol (2010) 0.96
Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH. Circ Cardiovasc Genet (2012) 0.96
Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol (1999) 0.93
A new approach to the management of familial hypercholesterolaemia: Removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet (1976) 0.92
Molecular characterization of familial hypercholesterolemia in Spain. Atherosclerosis (2011) 0.90
Biodistribution of AAV8 vectors expressing human low-density lipoprotein receptor in a mouse model of homozygous familial hypercholesterolemia. Hum Gene Ther Clin Dev (2013) 0.88
Colesevelam: a review of its use in hypercholesterolemia. Am J Cardiovasc Drugs (2007) 0.86
[Homozygous cutaneo-tendinous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis ans heroic treatment]. Bull Mem Soc Med Hop Paris (1967) 0.85
Low-density lipoprotein apheresis using double filtration plasmapheresis: 27-month use in a child with homozygous familial hypercholesterolemia. Ther Apher Dial (2010) 0.85
Italian multicenter study on low-density lipoprotein apheresis Working Group 2009 survey. Ther Apher Dial (2013) 0.82
Liver transplantation as treatment for familial homozygous hypercholesterolemia: too early or too late. Pediatr Transplant (2011) 0.81
Nutrition classics. Archives of Internal Medicine, Volume 64, October 1939: Angina pectoris in hereditary xanthomatosis. By Carl Müller. Nutr Rev (1987) 0.76
Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R). Clin Res Cardiol Suppl (2012) 0.76
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Major lipids, apolipoproteins, and risk of vascular disease. JAMA (2009) 10.58
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med (2012) 5.12
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol (2008) 2.75
Association between IVUS findings and adverse outcomes in patients with coronary artery disease: the VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging (2011) 2.43
B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation (2009) 2.37
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD). Eur Heart J (2011) 1.71
High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol (2010) 1.62
Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol (2005) 1.43
Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol (2005) 1.16
Comparison of effects of bare metal versus drug-eluting stent implantation on biomarker levels following percutaneous coronary intervention for non-ST-elevation acute coronary syndrome. Am J Cardiol (2006) 1.09
Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res (2013) 1.00
A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important? Int J Cardiol (2013) 0.98
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. J Am Coll Cardiol (2006) 0.96
Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trial. Am J Cardiol (2006) 0.90
Leukocyte telomere length is associated with high-risk plaques on virtual histology intravascular ultrasound and increased proinflammatory activity. Arterioscler Thromb Vasc Biol (2011) 0.89
Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf (2015) 0.89
Association of smoking with improved myocardial perfusion and the angiographic characterization of myocardial tissue perfusion after fibrinolytic therapy for ST-segment elevation myocardial infarction. J Am Coll Cardiol (2005) 0.87
Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost (2015) 0.86
Omega-3 Fatty acids and mortality outcome in patients with and without type 2 diabetes after myocardial infarction: a retrospective, matched-cohort study. Clin Ther (2012) 0.86
The effects of statins on blood pressure in normotensive or hypertensive subjects--a meta-analysis of randomized controlled trials. Int J Cardiol (2013) 0.85
Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Curr Med Res Opin (2013) 0.83
Diabetes: Which risk engines should be used to assess patients with diabetes? Nat Rev Endocrinol (2009) 0.83
Prognostic utility of neopterin and risk of heart failure hospitalization after an acute coronary syndrome. Eur Heart J (2011) 0.82
Intensive glucose lowering treatment in type 2 diabetes. BMJ (2011) 0.81
Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Thromb Thrombolysis (2012) 0.80
New worldwide lipid guidelines. Curr Opin Cardiol (2015) 0.79
Impact of statin therapy on plasma levels of plasminogen activator inhibitor-1. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost (2016) 0.77
Intensive statin therapy in acute coronary syndromes. Curr Atheroscler Rep (2008) 0.76
Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation (2002) 0.76
Guidelines in the USA, a viewpoint contrary to those guidelines in Europe, Canada, Britain and the International Atherosclerosis Society. Curr Opin Lipidol (2014) 0.76
Statins for people at low risk of cardiovascular disease. Lancet (2012) 0.76
Urinary albumin concentration and long-term cardiovascular risk in acute coronary syndrome patients: a PROVE IT-TIMI 22 substudy. J Thromb Thrombolysis (2013) 0.76
Undernutrition in adolescence and risk of cardiovascular disease. Eur Heart J (2011) 0.76
Statin treatment and the risk of recurrent pulmonary embolism. Eur Heart J (2013) 0.75
Aggressive statin therapy for acute coronary syndromes. Curr Cardiol Rep (2007) 0.75
Left ventricular noncompaction. J Cardiovasc Med (Hagerstown) (2011) 0.75
C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial). Am J Cardiol (2005) 0.75
Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe? Future Cardiol (2009) 0.75
[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. Turk Kardiyol Dern Ars (2015) 0.75